Stock TARA PROTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
2.75 USD +0.73% Intraday chart for Protara Therapeutics, Inc. -11.00% +46.66%
Apr. 05 Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition CI
Apr. 05 Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC CI

Evolution of the average Target Price on Protara Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e4.YZ0Mj4dNL_BVOd7zDNxPw6a0_of6k8bzFxP3WKeoHS8.LOVj4-MfXchgAYqnY5Aq-tzrkbWO-KmwdmeHLuzke1swrUu69hVLtidzhw~c1b03d9a346fef9800684e64082fc912

Analyst Recommendations on Protara Therapeutics, Inc.

Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating MT
Guggenheim Assumes Protara Therapeutics at Buy With $22 Price Target MT
HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $32, Maintains Outperform Rating MT
HC Wainwright Lowers Protara Therapeutics Price Target to $30 From $40, Buy Rating Kept MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $32 From $34, Maintains Outperform Rating MT
Oppenheimer Adjusts Price Target on Protara Therapeutics to $34 from $32, Keeps Outperform Rating MT
PROTARA THERAPEUTICS : BofA Securities Starts Protara Therapeutics at Buy With $15 Price Target MT
PROTARA THERAPEUTICS : HC Wainwright Starts Protara Therapeutics at Buy With $40 Price Target MT
PROTARA THERAPEUTICS : Oppenheimer Adjusts Protara Therapeutics PT to $32 From $43, Maintains Outperform Rating MT
PROTARA THERAPEUTICS : Oppenheimer Initiates Coverage on Protara Therapeutics With Outperform Rating, $43 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.75 USD
Average target price
27 USD
Spread / Average Target
+881.82%
High Price Target
50 USD
Spread / Highest target
+1,718.18%
Low Price Target
14 USD
Spread / Lowest Target
+409.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Protara Therapeutics, Inc.

Oppenheimer
Guggenheim
HC Wainwright
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TARA Stock
  4. Consensus Protara Therapeutics, Inc.